Kwesi Acquay is a principal at Redpoint Ventures, focused on investing in AI and enterprise software startups. Prior to Redpoint, Kwesi spent time at J.P. Morgan's tech investment banking practice where he worked on tech IPOs and M&A deals. Kwesi earned an MBA from Harvard Business School and graduated magna cum laude from Cornell University with a B.S. in Applied Economics and Management.
Cure Rare Disease, a non-profit organization (Tax ID number 82-2473513), is qualified as a tax-exempt organization under section 501(c)(3) of the IRS and has been designated as a “public charity” under section 170.